UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)

June 16, 2011

SUPERGEN, INC.

(Exact name of registrant as specified in its charter)

4140 Dublin Blvd., Suite 200

Dublin, CA 94568

(Address of principal executive offices, including zip code)

(925) 560-0100

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o            Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o            Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o            Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o            Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.07 — Submission of Matters to a Vote of Security Holders

The Annual Meeting of Stockholders of SuperGen, Inc., a Delaware corporation (the “Company”) was held on June 16, 2011.  The proposals submitted to a vote of the stockholders at the meeting are described in detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on May 2, 2011.  The final results of voting for each matter are as follows:

Proposal 1:                                     Approval of the issuance of (a) a number of shares of SuperGen common stock to certain former securityholders of Astex in connection with the Transaction equal to 35% of the outstanding stock of SuperGen after giving effect to the share issuance, plus an additional number of shares of SuperGen common stock potentially issuable in payment of some or all of the $30 million in deferred consideration, but in no event more than a total of 52.5 million shares of SuperGen common stock, and (b) a number of additional shares of SuperGen common stock potentially issuable upon exercise of certain options to be assumed by SuperGen in connection with the Transaction.

Proposal 2:                                     Approval to adjourn the annual meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of the issuances of shares in connection with the Transaction.

Proposal 3:                                     Election of the Board of Directors of the Company.

Proposal 4:                                     Approval of an amendment to the 2008 Employee Stock Purchase Plan increasing the number of shares of common stock authorized for issuance by 250,000 shares for a total of 500,000 shares reserved under the plan.

2

Proposal 5:                                     Ratification of Ernst & Young LLP as independent registered public accounting firm for the year ending December 31, 2011.

Proposal 6:                                     Advisory vote on compensation of named executive officers.

Proposal 7:                                     Advisory vote on the frequency of the advisory vote on compensation of named executive officers.

Each of Proposals 1 through 6 set forth above was approved, and a majority of stockholders advised that the frequency of advisory votes on compensation of named executive officers in Proposal 7 be “One Year.”  Based on this, the Company will include an advisory vote on named executive officer compensation in its proxy statement for each annual meeting of stockholders until the next advisory vote taken on the frequency of advisory votes on named executive officer compensation.

Item 8.01  Other Events.

On June 16, 2011, SuperGen issued a press release announcing that stockholders had approved the issuance of shares to be issued in connection with the proposed acquisition of Astex Therapeutics Limited, a UK corporation, pursuant to an Implementation Agreement dated April 6, 2011 (the “Transaction”).  Completion of the Transaction is still subject to a number of closing conditions and is expected to close in July 2011.

The press release is attached as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01  Financial Statements and Exhibits.

(d)  Exhibits

3

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date:  June 16, 2011

4

EXHIBIT INDEX

5